Precipio Inc. (PRPO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Precipio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kevin Stillman Evernest Financial Advisors, LLC | 10,600 | $188,574 | $237,864 | $49,290 | 26.14% |
Precipio Inc. (PRPO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Precipio Inc. ever had a stock split?
Precipio Inc. Profile
| Professional Services Industry | Industrials Sector | Ilan Danieli CEO | NASDAQ (CM) Exchange | 74019L503 CUSIP |
| US Country | 54 Employees | - Last Dividend | 22 Sep 2023 Last Split | 18 Jul 2000 IPO Date |
Overview
Precipio, Inc. is a healthcare solutions provider that specializes in diagnostic products, reagents, and services, primarily within the United States. This company focuses on delivering diagnostic testing services for blood cancers, utilizing innovative technology to facilitate accurate results. Their product portfolio includes proprietary cell culture media, genetic diagnostic panels, and COVID-19 antibody tests. Precipio, Inc. is headquartered in New Haven, Connecticut, and caters to bio-pharma customers with their ICE- technology kits, alongside their direct diagnostic services.
Products and Services
- IV-Cell:
A proprietary cell culture media developed by Precipio, Inc., IV-Cell is designed to enable the simultaneous culturing of four different hematopoietic cell lineages. This innovation supports more comprehensive and efficient blood cancer testing, facilitating the cultivation of various cells for better diagnostic accuracy.
- HemeScreen:
A suite of robust genetic diagnostic panels, HemeScreen is tailored to streamline the detection and analysis of genetic markers associated with blood cancers. These panels offer healthcare providers critical insights required for precise diagnosis and tailored treatment strategies, utilizing advanced genetic screening techniques.
- COVID-19 Antibody Tests:
In response to the global pandemic, Precipio, Inc. has expanded its diagnostic offerings to include COVID-19 antibody tests. These tests are designed to identify the presence of antibodies against the virus, indicating previous infection and possibly the extent of an individual’s immune response to COVID-19, hence contributing valuable data for public health and individual care decisions.
- ICE- Technology Kits:
Targeting bio-pharma customers, these technology kits leverage Precipio’s innovative ICE- technology, designed to enhance the efficacy and efficiency of pharmaceutical research and development. By providing cutting-edge tools for bio-pharmaceutical companies, Precipio, Inc. aids in the acceleration of research processes, potentially speeding up the time-to-market for new therapies.
